Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Clinical trial NCT06134271 · UNKNOWN

Trial details

NCT number: NCT06134271
Sponsor: Jianbin Bi
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Hormone-Sensitive Prostate Cancer

Start date: 2023-11-15
Primary completion: 2025-04-30
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.